MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $20.44 (119.83% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
Show:
DateFirmActionRatingPrice TargetActions
4/6/2016Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Jefferies GroupReiterated RatingHold$14.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Leerink SwannLower Price Target$36.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016WedbushReiterated RatingOutperform$38.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Bank of AmericaDowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2015FBR & Co.Reiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015OppenheimerReiterated RatingOutperform$53.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/2/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha